MedPath

Efficacy of Premedication Protocol Without Ranitidine for Taxane Regimen : A Multicenter Non-Randomized Historical Controlled Study

Phase 3
Completed
Conditions
Hypersensitivity reactions in patients who received taxane chemotherapy regimen between standard premedication protocol and modified premedication protocol without ranitidine.
Registration Number
TCTR20210322004
Lead Sponsor
/A
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
221
Inclusion Criteria

1. Cancer patients who received taxane chemotherapy regimen

Exclusion Criteria

1.History of severe Hypersensitivity reactions from taxane regimen
2.Severe hepatic impairment (bilirubin >5xULN or AST/ALT >10xULN)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Hypersensitivity reactions every 3 week of six-cycle course of chemotherapy grading of Hypersensitivity reactions
Secondary Outcome Measures
NameTimeMethod
/A N/A N/A
© Copyright 2025. All Rights Reserved by MedPath